Iambic Therapeutics, Inc.
Iambic Therapeutics is a company dedicated to transforming drug discovery through the integration of AI and seasoned drug hunters. Their mission is to develop superior medicines to address unmet patient needs by leveraging physics-based AI algorithms, high-throughput experimentation, and a proprietary pipeline to deliver first-in-class and best-in-class programs rapidly. They focus on innovative mechanisms of action, challenging targets, and broad therapeutic areas, aiming to create highly differentiated development candidates on a faster timeline than industry norms.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
IAM1363
Irreversible small-molecule tyrosine kinase inhibitor selective for HER2 and HER2 mutants with reported >1000-fold selectivity versus EGFR, CNS penetrance, favorable PK and preclinical efficacy; progressed into Phase 1 clinical dosing.
IAM-C1
First-in-class selective small-molecule inhibitor designed to target CDK2 and CDK4 while sparing other CDKs, intended to address cell-cycle dysregulation in cancer with a potentially improved safety profile.
KIF18A lead series
Allosteric small-molecule inhibitors targeting the KIF18A kinesin motor protein with single-digit nanomolar potency in biochemical and cell assays, reported selectivity and in vivo tumor growth inhibition driven by mitotic arrest.
Undisclosed GPCR allosteric agonist program
Allosteric agonist program targeting a GPCR for a neurological indication; program details and therapeutic hypothesis are undisclosed.
IAM1363
Irreversible small-molecule tyrosine kinase inhibitor selective for HER2 and HER2 mutants with reported >1000-fold selectivity versus EGFR, CNS penetrance, favorable PK and preclinical efficacy; progressed into Phase 1 clinical dosing.
IAM-C1
First-in-class selective small-molecule inhibitor designed to target CDK2 and CDK4 while sparing other CDKs, intended to address cell-cycle dysregulation in cancer with a potentially improved safety profile.
KIF18A lead series
Allosteric small-molecule inhibitors targeting the KIF18A kinesin motor protein with single-digit nanomolar potency in biochemical and cell assays, reported selectivity and in vivo tumor growth inhibition driven by mitotic arrest.
Undisclosed GPCR allosteric agonist program
Allosteric agonist program targeting a GPCR for a neurological indication; program details and therapeutic hypothesis are undisclosed.
Services
Collaborative service applying physics-based AI models, high-throughput design generation and automated experiments to advance external target programs and deliver differentiated development candidates faster.
Collaborative service applying physics-based AI models, high-throughput design generation and automated experiments to advance external target programs and deliver differentiated development candidates faster.
Expertise Areas
- AI-driven drug discovery
- Structure-based drug design
- Small-molecule lead discovery and optimization
- High-throughput experimentation and laboratory automation
Key Technologies
- Physics-based machine learning for chemistry
- Generative flow models for biomolecular complexes
- Equivariant transformers
- Multiscale generative diffusion models
News & Updates
Iambic was recognized for its innovative approach in AI-driven drug discovery and was named to CNBC’s 2025 Disruptor 50 List.
The company announced the completion of dose escalation in its Phase 1/1B clinical trial for IAM1363, a potent HER2 inhibitor.
Iambic revealed its new AI model, Enchant v2, designed to improve predictions of clinical success in drug discovery.
The company announced its participation in upcoming investor conferences in June 2025.
A news article highlighting Iambic's recent breakthroughs in AI-driven drug discovery, supported by Nvidia.
Coverage of Iambic's recognition on CNBC’s Disruptor 50 List for 2025.
Iambic was recognized for its innovative approach in AI-driven drug discovery and was named to CNBC’s 2025 Disruptor 50 List.
The company announced the completion of dose escalation in its Phase 1/1B clinical trial for IAM1363, a potent HER2 inhibitor.
Iambic revealed its new AI model, Enchant v2, designed to improve predictions of clinical success in drug discovery.
The company announced its participation in upcoming investor conferences in June 2025.
A news article highlighting Iambic's recent breakthroughs in AI-driven drug discovery, supported by Nvidia.
Coverage of Iambic's recognition on CNBC’s Disruptor 50 List for 2025.